New drug trial hopes to tame rare blood cancers

NCT ID NCT07008118

First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 25 times

Summary

This early-stage study tests a new drug, INCA035784, for safety in 120 adults with myeloproliferative neoplasms (MPNs), a group of rare blood cancers. Participants must have a specific gene mutation (CALR) and have tried other treatments. The main goal is to check for side effects, not to cure the disease. The study is currently recruiting.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOPROLIFERATIVE NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Azienda Ospedaliero Universitaria Careggi-S.O.D. Patologia Medica

    NOT_YET_RECRUITING

    Florence, 50134, Italy

  • Azienda Socio Sanitaria Territoriale Papa Giovanni Xxiii

    NOT_YET_RECRUITING

    Bergamo, 24127, Italy

  • Centro Ricerche Cliniche Di Verona

    NOT_YET_RECRUITING

    Verona, 37134, Italy

  • Cliniques Universitaires Saint-Luc

    NOT_YET_RECRUITING

    Brussels, 01200, Belgium

  • Colorado Blood Cancer Institute

    RECRUITING

    Denver, Colorado, 80218, United States

  • Fondazione Irccs Ca Granda Ospedale Maggiore

    NOT_YET_RECRUITING

    Milan, 20122, Italy

  • Huntsman Cancer Institute At University of Utah

    RECRUITING

    Salt Lake City, Utah, 84112, United States

  • Icahn School of Medicine At Mount Sinai

    RECRUITING

    New York, New York, 10029, United States

  • Johns Hopkins University

    NOT_YET_RECRUITING

    Baltimore, Maryland, 21287, United States

  • Linear Clinical Research

    RECRUITING

    Nedlands, Western Australia, 06009, Australia

  • Macquarie University Hospital

    RECRUITING

    Sydney, New South Wales, 02109, Australia

  • Mayo Clinic Hospital

    NOT_YET_RECRUITING

    Phoenix, Arizona, 85054, United States

  • Mayo Clinic-Florida

    NOT_YET_RECRUITING

    Jacksonville, Florida, 32224, United States

  • Medical College of Wisconsin

    RECRUITING

    Milwaukee, Wisconsin, 53226, United States

  • Royal Adelaide Hospital

    RECRUITING

    Adelaide, South Australia, 05000, Australia

  • South Austin Medical Center

    RECRUITING

    Austin, Texas, 78704, United States

  • Stanford University

    RECRUITING

    Palo Alto, California, 94304, United States

  • The Alfred Hospital

    RECRUITING

    Melbourne, Victoria, 03004, Australia

  • Universitaetsklinikum Dresden

    NOT_YET_RECRUITING

    Dresden, 01307, Germany

  • Universitair Ziekenhuis Gent

    NOT_YET_RECRUITING

    Ghent, 09000, Belgium

  • Universitaire Ziekenhuizen Leuven

    NOT_YET_RECRUITING

    Leuven, 03000, Belgium

  • Universitatsklinikum Halle (Saale)

    NOT_YET_RECRUITING

    Halle, 06120, Germany

  • Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii

    NOT_YET_RECRUITING

    Mainz, 55131, Germany

  • University of Chicago Medical Center

    NOT_YET_RECRUITING

    Chicago, Illinois, 60637, United States

  • University of North Carolina At Chapel Hill

    RECRUITING

    Chapel Hill, North Carolina, 27514, United States

  • University of Texas Southwestern Medical Center Harold C Simmons Comprehensive Cancer Center Blood

    NOT_YET_RECRUITING

    Dallas, Texas, 75235, United States

Conditions

Explore the condition pages connected to this study.